Accordingly, we recently reported that the progression of established human breast tumor cell xenografts in the nude mice is suppressed by targeting surface nucleolin with a specific antagonist, the HB-19 pseudopeptide, that binds the RGG domain of nucleolin [13], [16]. This evidence concerns the gene NUCLEOLIN and breast neoplasm.